Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543678 | 0.74 | CRHR1 (0.67) | CRHR1GAA | |
| SCHEMBL7537463 | 0.71 | CRHR1 (0.57) | CRHR1KDM4EALDH1A1 | |
| SCHEMBL62708 | 0.63 | CRHR1 (0.75) | CRHR1 | |
| SCHEMBL61586 | 0.62 | CRHR1 (0.79) | CRHR1 | |
| SCHEMBL62629 | 0.61 | CRHR1 (0.75) | CRHR1 | |
| SCHEMBL28148154 | 0.57 | CA1 (0.65) | KDM4EALDH1A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL30203585 | 0.56 | ERN1 (0.66) | KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL25390259 | 0.56 | HSP90AA1 (0.43) | ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30570371 | 0.56 | HSP90AA1 (0.43) | ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL544418 | 0.55 | ABCG2 (0.53) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233949-A2 | 5-SUBSTITUTED ARYLPYRIMIDINES | NEUROGEN CORPORATION (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020072521-A1 | 5-substituted arylpyrimidines | NEUROGEN CORPORATION | 2002-06-13 | — | — | US | disclosed |
| WO-2001068614-A2 | 5-SUBSTITUTED ARYLPYRIMIDINES | NEUROGEN CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072521-A1 | 5-substituted arylpyrimidines | HTR5A, CRHR1, HTR4 | CRHR1 2/4885KDM4E 1754/4885NPC1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.